DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Abstract Text:

C F Lippa,J E Duda,M Grossman,H I Hurtig,D Aarsland,B F Boeve,D J Brooks,D W Dickson,B Dubois,M Emre,S Fahn,J M Farmer,D Galasko,J E Galvin,C G Goetz,J H Growdon,K A Gwinn-Hardy,J Hardy,P Heutink,T Iwatsubo,K Kosaka,V M-Y Lee,J B Leverenz,E Masliah,I G McKeith,R L Nussbaum,C W Olanow,B M Ravina,A B Singleton,C M Tanner,J Q Trojanowski,Z K Wszolek, ,

For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of alpha-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal alpha-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of alpha-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for alpha-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Publishing Authors By Initials

CF Lippa,JE Duda,M Grossman,HI Hurtig,D Aarsland,BF Boeve,DJ Brooks,DW Dickson,B Dubois,M Emre,S Fahn,JM Farmer,D Galasko,JE Galvin,CG Goetz,JH Growdon,KA Gwinn-Hardy,J Hardy,P Heutink,T Iwatsubo,K Kosaka,VM Lee,JB Leverenz,E Masliah,IG McKeith,RL Nussbaum,CW Olanow,BM Ravina,AB Singleton,CM Tanner,JQ Trojanowski,ZK Wszolek, ,

For similar nervous system diseases: central nervous system diseases: brain diseases: basal ganglia diseases: parkinsonian disorders: parkinson disease research abstracts see: nervous system diseases: central nervous system diseases: brain diseases: basal ganglia diseases: parkinsonian disorders: parkinson disease research

PUBMED ID PMID:

MEDLINE DATE:

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Journal Published:

PUBLICATION TYPE: Review

Journal: Neurology

VOLUME: 68

Page Numbers: 812-9

Journal Abbreviation: Neurology

ISSN: 1526-632X

DAY: 13

MONTH: Mar

YEAR: 2007

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Information

Number of References: 87

LANGUAGE: eng

NlmUniqueID: 401060

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Keywords Mesh Terms:

KEYWORDS: Parkinson Disease

MESH TERMS: therapy

Chemical & Substance for Abstract: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Information

Substance Name: Biological Markers

Registry Number: 0

Grant and Affiliation Information for DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.

AFFILIATION: Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA. clippa@drexelmed.edu

Country: United States

AGENCY: United States NINDS

GRANT: NS054546-01

ACRONYM: NS

MEDLINETA: Neurology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers Related Publications

• Clinical and genetic features of families with frontotemporal dementia and parkinsonism linked to chromosome 17 with a P301S tau mutation.
• DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
• Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies.
• Familial parkinsonism: Our experience and review.
• Frontotemporal dementia and Parkinsonism linked to chromosome 17 with the N279K tau mutation.
• Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids.
• Is there a genetic susceptibility to idiopathic parkinsonism?
• Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.
• MR imaging of brainstem atrophy in progressive supranuclear palsy.
• Rapidly progressive familial parkinsonism with central hypoventilation, depression and weight loss (Perry syndrome)-A literature review.
• Uncertainty of airborne sound insulation index measurement in laboratory conditions.